Biocon Ltd., a biopharmaceutical company based in India, develops, manufactures and supplies products to treat diabetes, cancer, and autoimmune conditions. Last week, Biocon launched KRABEVA®, a bevacizumab biosimilar for the treatment of metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian, and brain cancers in India.
Biocon reports that KRABEVA® is being introduced “with an innovative temperature-sensitive packaging that includes thermo-chromic stickers, which change colour irreversibly if the cold chain temperature is not maintained. This first-of-its-kind ‘Qual Check’ feature ensures quality check of the product up to the point of administration to the patient.” Biocon states in its press release that “[t]his will provide greater confidence to physicians and healthcare professionals about the quality of the product they are dispensing and will enable better patient safety.”
The post Biocon Ltd Launches Bevacizumab Biosimilar in India appeared first on Goodwin Procter BioSimilars Blog.